US Patent

US8623826 — Compositions and methods for treating centrally mediated nausea and vomiting

Method of Use · Assigned to Helsinn Healthcare SA · Expires 2030-11-18 · 5y remaining

Vulnerability score 73/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects methods for treating nausea and vomiting in patients undergoing chemotherapy, radiotherapy, or surgery by co-administering netupitant, palonosetron, and dexamethasone.

USPTO Abstract

Provided are methods for treating nausea and vomiting in patients undergoing chemotherapy, radiotherapy, or surgery, comprising the co-administration of netupitant, palonosetron and dexamethasone.

Drugs covered by this patent

Akynzeo (NETUPITANT) · Helsinn Hlthcare

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2293`	—	Akynzeo

Patent Metadata

Patent number: US8623826
Jurisdiction: US
Classification: Method of Use
Expires: 2030-11-18
Drug substance claim: No
Drug product claim: No
Assignee: Helsinn Healthcare SA
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.